OncoMatch/Clinical Trials/NCT07670221
Nurse-Led Self-Management Program on Taste Alteration in Women With Breast Cancer
Is NCT07670221 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies non-drug interventions for chemotherapy-related taste alteration.
Taste alteration is a common and distressing symptom experienced by women with breast cancer receiving taxane-based chemotherapy. This symptom may negatively affect food intake, nutritional status, psychological well-being, and quality of life. Although several approaches have been suggested for the management of chemotherapy-related taste alteration, evidence regarding structured nurse-led self-management interventions in this patient group remains limited.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Excluded: Stage METASTASIS
Having metastasis [excluded]
Demographics
Prior therapy
Must have received: taxane
Receiving taxane-based chemotherapy
Cannot have received: radiation therapy
Receiving radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07670221 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages